Trending Now
Recession-free stocks to place on top of radar (DG,TGT,DLTR,GOOG,BIG)
Only time will tell if we are heading into a recession as the central bank’s aggressive rate hikes start to slow the...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
NeuroSense Therapeutics Ltd (NASDAQ: NRSN) Receives Clearance For Pharmacokinetic Study of ...
NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has announced that the FDA has given it clearance to commence a pharmaceutical study of PrimeC in healthy adult...
MAKE IT MODERN
LATEST REVIEWS
Porch Group, Inc. (PRCH): Strong Q3 Performance Drives 55% Stock Surge...
Porch Group, Inc. (NASDAQ: PRCH), a comprehensive homeowners insurance and vertical software platform, experienced a remarkable 55.36% increase in its stock price,...
MAKE IT MODERN
PERFORMANCE TRAINING
Silverback Therapeutics Inc. (NASDAQ: SBTX) Reports Phase 1/1b SBT6050 Study Data In Combination With...
Silverback Therapeutics Inc. (NASDAQ: SBTX) has presented interim results from its Phase1/1b SBT6050 clinical study as a monotherapy and combined with pembrolizumab in metastatic...
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Provides Updates Of Its 2020 Achievements And Future Strategy
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) has highlighted is achievements in 2020 and offered a strategy that will help its realize considerable opportunity for...
Kintara Therapeutics Inc. (NASDAQ: KTRA) Releases Topline Data from Open-Label GBM Clinical Study
Kintara Therapeutics Inc. (NASDAQ: KTRA) has announced topline data from its newly-diagnosed adjuvant arm of the open-label second phase clinical trial being carried at the...
Outlook Therapeutics Inc (NASDAQ:OTLK) Completes The Evaluation Of ONS-5010/LYTENAVA To Cure Retinal Diseases
Outlook Therapeutics Inc (NASDAQ:OTLK) completed the evaluation study of ONS-5010/LYTENAVA with the first final visit of the last patient.
Completes two clinical trials
In the open-label...
ARCA Biopharma Inc. (NASDAQ:ABIO) Is Developing AB201Program As A Possible COVID-19 Treatment
ARCA Biopharma Inc. (NASDAQ:ABIO) is developing a new program for evaluating AB201 (rNAPc2). It is a selective tissue factor inhibitor for treating coronavirus related...
MAKE IT MODERN
